Russell Schuster III Sells 11,275 Shares of AdaptHealth (NASDAQ:AHCO) Stock

AdaptHealth Corp. (NASDAQ:AHCO) insider Russell Schuster III sold 11,275 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $10.06, for a total value of $113,426.50. Following the completion of the sale, the insider owned 136,538 shares in the company, valued at approximately $1,373,572.28. This represents a 7.63% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

AdaptHealth Price Performance

Shares of NASDAQ AHCO opened at $9.73 on Friday. The business’s 50 day moving average price is $11.53 and its 200 day moving average price is $10.55. The firm has a market cap of $1.32 billion, a P/E ratio of -15.69, a P/E/G ratio of 0.55 and a beta of 1.47. AdaptHealth Corp. has a 52 week low of $8.06 and a 52 week high of $13.43. The company has a quick ratio of 0.71, a current ratio of 0.92 and a debt-to-equity ratio of 1.21.

AdaptHealth (NASDAQ:AHCO) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.13). AdaptHealth had a positive return on equity of 2.76% and a negative net margin of 2.42%.The company had revenue of $819.80 million during the quarter, compared to analysts’ expectations of $796.63 million. During the same quarter in the prior year, the company posted ($0.05) EPS. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. On average, sell-side analysts expect that AdaptHealth Corp. will post 0.63 earnings per share for the current year.

Analysts Set New Price Targets

AHCO has been the topic of several recent research reports. Royal Bank Of Canada upped their price objective on AdaptHealth from $13.00 to $15.00 and gave the stock an “outperform” rating in a research report on Monday, May 11th. Truist Financial upped their price objective on AdaptHealth from $13.00 to $14.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Robert W. Baird set a $18.00 price objective on AdaptHealth in a research report on Wednesday, May 6th. Jefferies Financial Group restated a “hold” rating and issued a $11.00 price objective on shares of AdaptHealth in a research report on Monday, April 20th. Finally, Canaccord Genuity Group upped their price objective on AdaptHealth from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $14.29.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in AHCO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of AdaptHealth by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 60,495 shares of the company’s stock worth $656,000 after buying an additional 2,564 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of AdaptHealth by 32.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 571,232 shares of the company’s stock worth $6,192,000 after buying an additional 139,828 shares during the period. Woodline Partners LP acquired a new position in shares of AdaptHealth during the 1st quarter worth approximately $2,851,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of AdaptHealth by 18.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 233,780 shares of the company’s stock worth $2,534,000 after buying an additional 35,879 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in shares of AdaptHealth by 1.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 211,769 shares of the company’s stock worth $1,997,000 after buying an additional 2,718 shares during the period. 82.67% of the stock is owned by institutional investors and hedge funds.

AdaptHealth Company Profile

AdaptHealth, Inc operates as a leading provider of home medical equipment (HME) and related services in the United States. The company focuses on delivering respiratory care, mobility solutions and bathroom safety products to patients with chronic and acute medical needs. Through its comprehensive service offerings, AdaptHealth aims to enhance quality of life and clinical outcomes for patients who require long-term support outside of a hospital setting.

The company’s respiratory portfolio includes products such as continuous positive airway pressure (CPAP) devices, oxygen concentrators, ventilators, and associated supplies for patients with sleep apnea, COPD and other pulmonary conditions.